CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 27 enrolled
Drug / intervention
Doxorubicin +3 moredrug
Likely dose
Doxorubicin 10 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01882816
NCT01882816Phase 2Completed

A Phase II Study of Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer

Memorial Sloan Kettering Cancer Center·interventional·Posted Jun 20, 2013·Updated Dec 29, 2022

In Brief

A Phase 2 clinical trial evaluating IMRT, DWI MRI, and 2 other interventions for Thyroid Cancer. Completed, enrolled 27 participants across 6 sites.

Detailed Summary

The purpose of this Phase 2 study is to find out what effect, good and/or bad, external beam radiation therapy, has on the patient and their thyroid cancer where surgery is not an option or where despite surgery, the disease is still present.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsThyroid Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 20, 2013
Enrollment StartJun 13, 2013
Primary CompletionNov 4, 2021
TodayJul 1, 2026
Enrollment to primary: 8.4 yearsPosted 13.0 years ago

Interventions

IMRTradiation

Patients will receive intensity-modulated radiation therapy (IMRT) in once-daily fractions (Monday through Friday, excluding holidays). A total dose of 70Gy is planned. Patients will be seen weekly during radiation as per standard procedure at MSKCC

DWI MRIdevice

The DW and multiparametric MRI will be recommended for 3 months, 6 months, and then every 6 months (all +/- 4 weeks) until 2 years post-RT unless contraindicated for main campus patients only. This schedule may be altered, as clinically indicated.

Doxorubicindrug

Low dose radiosensitizing doxorubicin at 10 mg/m2 will be administered weekly.

Modified Barium Swallow Impairment Profile (MBSImP)other

The MBSImP is a standardized tool which assesses swallowing impairment as it relates to oral, pharyngeal, and esophageal impairments.